We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Human Trial of Pill That Could Reduce COVID-19 Related Lung Damage Begins At First US Clinical Trial Site

By HospiMedica International staff writers
Posted on 11 Aug 2020
Print article
Illustration
Illustration
Ifenprodil, a drug in pill form repurposed by Algernon Pharmaceuticals (Vancouver, BC, Canada) to treat COVID-19 damage in the lungs, is being tested as a possible treatment on coronavirus patients for the first time in the US.

The Westchester General Hospital in Miami, Florida, is the first American research center to test the Ifenprodil pill that was developed in the 1970s to treat blood circulation disorders and could help reduce some COVID-19 side-effects in the lungs. Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB) and prevents glutamate signaling. The NMDA receptor is found on several tissues, including lung cells, T-cells, and neutrophils.

Algernon began exploring Ifenprodil (NP-120) as a possible treatment for COVID-19 when it discovered an independent research study that showed the drug was active in an animal model for H5N1, the world’s most lethal avian flu, with an approximately 60% mortality rate in humans. In the study, Ifenprodil reduced mortality by 40% and reduced acute lung injury and inflammation in the lung tissue. Following its own animal data showing Ifenprodil’s reduction of lung fibrosis in two separate studies, the company is investigating Ifenprodil to determine if it can reduce the severity and duration of a COVID infection. Algernon believes that Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients.

Algernon has completed its clinical trial agreement with Westchester Research Center at Westchester General Hospital in Miami, Florida, for its multinational Phase 2b/3 human study of Ifenprodil for COVID-19 and is in final contractual negotiations with four additional US clinical sites. The company has already received ethics approval from a central institutional review board for all of the US study sites. The company is also in the final stages of completing contractual negotiations and receiving ethics approval in Australia, Romania and the Philippines.

“Of the five US research institutions we have been working with, two are located in Florida where they have recently had a significant number of confirmed COVID-19 cases,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “We look forward to working with Dr. Gonzalez and appreciate her work in helping to get the trial started at Westchester General as soon as possible.”

Related Links:

Algernon Pharmaceuticals

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Mobile Digital X-Ray System
SOLTUS 500

Print article

Channels

Critical Care

view channel
Image: A full readout from the new AI algorithm that helps read EEGs (Photo courtesy of Duke University)

AI Doubles Medical Professionals’ Accuracy in Reading EEG Charts of ICU Patients

Electroencephalography (EEG) readings are crucial for detecting when unconscious patients may be experiencing or are at risk of seizures. EEGs involve placing small sensors on the scalp to measure the... Read more

Surgical Techniques

view channel
Image: GI procedures can produce dangerous levels of smoke (Photo courtesy of 123RF)

Study Warns Against Dangerous Smoke Levels Produced During Endoscopic Gastrointestinal Procedures

Healthcare professionals involved in certain smoke-generating endoscopic gastrointestinal procedures, such as those using electrical current to excise polyps, may be exposed to toxin levels comparable... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: POCT offers cost-effective, accessible, and immediate diagnostic solutions (Photo courtesy of Flinders University)

POCT for Infectious Diseases Delivers Laboratory Equivalent Pathology Results

On-site pathology tests for infectious diseases in rural and remote locations can achieve the same level of reliability and accuracy as those conducted in hospital laboratories, a recent study suggests.... Read more